AbCellera Biologics Aktie
WKN DE: A2QKXS / ISIN: CA00288U1066
29.08.2024 22:05:00
|
AbCellera to Present at Upcoming Investor Conferences in September
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
- Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time)
- Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829861441/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbCellera Biologics Inc Registered Shsmehr Nachrichten
06.08.25 |
Ausblick: AbCellera Biologics legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
24.07.25 |
Erste Schätzungen: AbCellera Biologics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
07.05.25 |
Ausblick: AbCellera Biologics stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
23.04.25 |
Erste Schätzungen: AbCellera Biologics präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu AbCellera Biologics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
AbCellera Biologics Inc Registered Shs | 3,94 | 1,94% |
|